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Abstract
The current global novel coronavirus disease 2019 (COVID-19) pandemic threatens to derail the uptake of human
papillomavirus (HPV) vaccination in low- and lower-middle income countries with major disruptions to routine immuniza-
tion and the introduction of new vaccines delayed. This has a major impact on the World Health Organization cervical cancer
elimination strategy, where it is dependent on HPV vaccination as well as cervical cancer screening and treatment. We dis-
cuss current opportunities and barriers to achieve high uptake of HPV vaccination in low- and lower-middle income countries
as well as the impact of COVID-19. Implementation of 4 key recommendations for HPV vaccination in low- and lower-middle
income countries is needed: increased global financial investment; improved vaccine supply and accelerated use of a single-
dose schedule; education and social marketing; and adoption of universal school-based delivery. With the commitment of
the global health community, the adoption of these strategies would underpin the effective elimination of cervical cancer.
Cervical cancer is the fourth most common cancer in women
worldwide, with 570 000 cases each year causing 311 000 deaths,
mostly in low- and lower-middle income countries (LLMICs) (1,
2). It is caused by chronic infection with oncogenic genotypes of
human papillomavirus (HPV), but unlike most cancers, it is
largely preventable by vaccination. In 2018, the director-general
of the World Health Organization (WHO) made a pledge to elim-
inate cervical cancer as a public health problem within the next
century. Elimination is defined as an incidence of less than 4
cases per 100 000 women-years. Clear targets that have been set
by 2030 to achieve the “elimination goal” include the following:
90% of girls to be immunized by 15 years of age; 70% of women
between 35 and 45 years old to be screened at least once in a
lifetime with a proficiency test; and 90% of women with high-
grade cervical lesions or cervical cancer being treated (3).
Whereas some high-income countries (HICs) such as the
United Kingdom and Australia are on track to eliminate cervical
cancer within the next decade as a result of high HPV vaccine
coverage rates and robust screening programs as well as access
to treatment for precancerous and early stage cancerous lesions
(4,5), the situation in LLMICs is far less optimistic. Of the 131
countries that have introduced the HPV vaccine (Romania,
Lesotho, and Kazakhstan have since stopped; Japan suspended)
(6), less than 20% of countries are LLMICs. Furthermore, 70% of
the target global population of 9- to 14-year-old girls currently
live in a country without an HPV immunization program (7).
More than 44 million women will be diagnosed with cervical
cancer in the next 50 years if primary and secondary prevention
programs are not implemented in LLMICs (8). Although strate-
gies to prevent, screen, and treat are necessary for cervical can-
cer elimination, primary prevention of HPV infection through
HPV immunization in LLMICs is likely to have the greatest long-
term impact and represents the most feasible approach to per-
manently reduce the global cervical cancer burden.
There has been a growing global momentum toward the in-
troduction of the HPV vaccine in LLMICs. As of 2020, 52 LLMICs
have conducted pilot or demonstration projects, and almost
half have introduced HPV vaccine in their national program in
the last 5 years (6). Bhutan and Rwanda were 2 of the first
LLMICs to successfully introduce HPV vaccine, achieving high
vaccine coverage (>90%) in the target population, demonstrat-
ing the feasibility of a successful HPV immunization program in
LLMICs. Another 41 countries and territories are projected to in-
troduce HPV vaccine in their national schedule by the end of
2023 (6). However, the uptake of HPV vaccination in LLMICs fol-
lowing successful pilot programs, as well as in those countries
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unable to introduce HPV vaccine in the near future, was already
dependent on overcoming major barriers such as high vaccine
and programmatic costs, HPV vaccine shortages, vaccine hesi-
tancy, and suitable vaccine delivery strategies (Figure 1).
On March 11, 2020, the WHO declared novel coronavirus dis-
ease 2019 (COVID-19) a global pandemic, caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). The outbreak
was first identified in Wuhan, China, in December 2019. As of
October 7, 2020, more than 35 million cases and 1 million deaths
due to COVID-19 have been reported in more than 188 countries
and territories (9). Unprecedented public health and social
measures (ie, closure of international borders, movement
restrictions within countries, and partial or complete closure of
schools and businesses, as well as strict quarantine practices)
have been implemented across the globe to curb the spread of
the virus and prevent overwhelming the health-care systems.
The COVID-19 pandemic has had profound impact on com-
munities, causing disruptions to many essential health services,
including the provision of routine immunization services (10).
These are due to factors such as transport interruptions, health
workers being unavailable because of safety and health con-
cerns, travel restrictions, or redeployment to COVID-19 re-
sponse duties, as well as a lack of personal protective
equipment (PPE) (10). The restrictions on movement, or fear of
being exposed to people with COVID-19, have also seen people
reluctant to leave home to get immunized (10). It is estimated
that 80 million children under the age of 1 year in at least 68
countries will miss out on essential vaccines, predisposing
them to severe diseases (11). Gavi, the Vaccine Alliance, is a
partnership of public and private sectors that help improve ac-
cess to new and underused vaccines for the most vulnerable
children in low-income countries (gross domestic product <
US$3000). It is estimated that at least 24 million children and
adolescents living in 21 Gavi-supported lower-income countries
are also at risk of missing out on life-saving vaccines such as
HPV vaccine because of postponed campaigns and delayed in-
troduction of new vaccines (11). By June 2020, 45 out of 68 Gavi-
supported vaccine introductions have already been affected by
shipment delays and low vaccine stocks (10). Modeled data sug-
gest that the deaths prevented by sustaining routine childhood
Figure 1. Overcoming the barriers in the uptake of human papillomavirus (HPV) vaccination in low- and lower-middle-income countries
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immunization in Africa far outweigh the excess risk of COVID-
19 deaths associated with vaccination clinic visits, especially for
the vaccinated children (12). This is likely to be true for HPV vac-
cination, where the pandemic is exacerbating the barriers and
threatening the progress already made toward HPV vaccine in-
troduction in LLMICs over the last decade. Therefore, proactive
deployment of intervention strategies is urgently needed by the
global health community. In this viewpoint, we discuss the ma-
jor barriers to HPV vaccination in LLMICs, the effects of COVID-
19, and the strategies now needed to increase the uptake of HPV
vaccination.
Barriers to HPV Vaccine Uptake and Impact of
COVID-19 Pandemic
High Vaccine and Programmatic Costs
High vaccine and programmatic costs (including vaccine cold
chain storage, staff, and transport of large quantities of vac-
cines) are major barriers to access HPV vaccine in many LLMICs.
In the last 10 years, Gavi has enabled access to subsidized HPV
vaccine (20% of the Gavi purchase price, currently around $4.50
per dose) and supported HPV vaccine programs for the poorest
countries in the world. In 2016, Gavi initiated an accelerated
HPV vaccine program where an estimated 40 million girls from
Gavi-eligible countries were expected to receive the vaccine by
2020, thereby averting 900 000 deaths (13). However, this num-
ber was reduced to 14 million because of the increased global
demand and subsequent shortage of HPV vaccine (see below;
HPV Vaccine Supply). Although Gavi provides substantial
resources to kick-start the HPV vaccine program, sustainable fi-
nancing mechanisms and the commitment from governments
are necessary for these countries as they graduate from Gavi
status in the coming years to maintain their HPV immunization
program. In most cases, the cost of HPV vaccine is critical. This
is where financial support for vaccine procurement and/or price
negotiation with vaccine manufacturers from international
health agencies such as the Pan American Health Organization,
Program for Appropriate Technology in Health, United Nations
International Children’s Emergency Fund (UNICEF), and the Gulf
Cooperation Council become extremely important for countries
planning to introduce HPV vaccine nationally but are not eligi-
ble for Gavi funding (ie, middle-income countries).
The COVID-19 pandemic has restricted vaccine access
(not limited to HPV) in many LLMICs. The economic impact
of COVID-19 has led to a global recession, which will un-
doubtedly lead to reduced national income and health budg-
ets, increased public and private debt, and reduced access to
vaccines and vaccine delivery services. Access to HPV vac-
cine, like other vaccines, will be even more challenging than
before, and the recession threatens to roll back the hard-won
progress that LLMICs have made in recent decades. Some
LLMICs however, such as Lao People’s Democratic Republic
and Uganda, have continued routine immunization services
in the face of COVID-19 through support from Gavi and
UNICEF, government leadership, and community engage-
ment (14,15). Specifically, the support from global health
leaders in vaccine procurement, PPE provision, diagnostics,
training and communication campaigns, and most impor-
tantly, strong support and advocacy by government minis-
tries is crucial in the continuation of immunization services
in response to the COVID-19 pandemic. Lessons learned from
these countries would help facilitate vaccine
implementation in some of the poorest countries and most
remote communities for the current pandemic and future
outbreaks. Indeed, some of these countries (ie, Nepal, Niger,
and Syria), with the help of UNICEF, have been able to con-
tinue immunization services for children (16). One of the
highest global priorities now is to restore immunization serv-
ices, including HPV vaccination, provided it is safe to do so
with strict public health measures in place (ie, use of PPE and
physical distancing).
Emerging evidence suggests that a single dose of HPV vac-
cine is immunogenic and sufficient for protection against
HPV infection and potentially HPV-associated diseases over
the long term (17-21). Although considerable investment is
still required for delivery of a single-dose HPV vaccine pro-
gram, it remains highly cost-effective compared with other
health interventions, and substantial cost-savings over the
long-term will be achieved because of reductions in cervical
cancer treatment costs (22,23). Formal randomized con-
trolled trials are underway to examine a single-dose HPV
schedule, and results from these studies are greatly antici-
pated within the next 5 years (24). The provision of a single
dose of HPV vaccine during these difficult times may help
bridge the issues of vaccine cost and logistical constraints. A
second dose may be administered at a later time if needed, in
the period following this pandemic.
HPV Vaccine Supply
Because of the increased global demand of HPV vaccine (more
than double the demand in 2018 compared with 2017) as a re-
sult of more publicly funded programs and a move toward
gender-neutral vaccination and multi-age cohort catch-up cam-
paigns, there is now a global shortage of HPV vaccine (25). Many
LLMICs now have to delay the introduction of the HPV vaccine.
For example, in 2018, the Ethiopian government had planned
for a multi-age cohort HPV vaccine national introduction (9-
14 years old) but were only able to vaccinate 14-year-old girls be-
cause of the global vaccine shortage (Mulholland K, personal
communication). Although the vaccine manufacturers are cur-
rently expanding their production including building new facili-
ties to meet global demand, this still requires long lead times
(up to 4 years), including the necessary regulatory approvals
(26). Production is not expected to meet demand until 2024 at
the earliest. Reallocating vaccines from one country to another
is also complicated and unlikely given differing regulatory
requirements across countries.
It is uncertain if the COVID-19 pandemic has affected the
timeline of vaccine production to meet global demand. At the
recent Global Vaccine Summit in May 2020, HPV vaccine manu-
facturers (existing and new) committed to provide sufficient
supply of HPV vaccines for Gavi-supported countries by 2025,
enabling 84 million girls much-needed access to this vaccine
(27). Although this positive news may not necessarily provide
immediate relief during the pandemic, countries where routine
immunization of HPV vaccine has been disrupted can initiate
plans for future catch-up campaigns to adolescents who may
have missed HPV vaccination during the COVID-19 pandemic.
In the longer term, access to HPV vaccines will also improve
with the development of new, low-cost, and quicker-to-produce
HPV vaccines that are expected to come onto the market over
the next few years. One of these is a bivalent HPV vaccine
(CecolinVR , Xiamen Innovax Biotech CO., LTD., China) recently li-
censed in China, and a further 2 candidates are currently in
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phase III clinical trials (a bivalent vaccine from Walvax
Biotechnology Co. Ltd, China, and a quadrivalent vaccine from
Serum Institute of India, India) (28).
Ensuring sufficient supply of HPV vaccines and rollout of tar-
geted catch-up programs will be key to ensure the most vulner-
able populations are not predisposed to cervical cancer and
other HPV-associated diseases. The use of single-dose HPV vac-
cine schedules or delaying the second dose of vaccine by at least
2 to 3 years once the results of the single-dose trials are avail-
able would alleviate the vaccine supply issue (26). Female-only
HPV programs should be the priority during this period, with
WHO (Strategic Advisory Group of Experts on Immunization
Committee) recommending temporary suspension of gender-
neutral and multibirth cohort vaccination programs, although
this may be difficult in countries with an established HPV vac-
cine program. These recommendations are endorsed by the
International Papillomavirus Society (IPVS), the preeminent so-
ciety for basic science, clinical, and public health research on
papillomavirus (26). Temporary suspension of gender-neutral
vaccination programs is unlikely to have a major impact on the
cervical cancer elimination strategy, although the changing rec-
ommendation for established gender-neutral programs may
cause public confusion. It is therefore important to highlight
that girls in LMICs, where cervical cancer burden is highest, are
most in need of the vaccine but currently do not have access to
it. Vaccinating girls will have the greatest impact on the global
burden of cervical cancer because cervical cancer is the most
important disease caused by HPV. A catch-up vaccination pro-
gram for boys may be offered to accelerate cervical cancer elimi-
nation and prevent other HPV-associated diseases when
vaccine supply meets demand (29). Such drastic changes in the
current thinking are needed if we are to meet the challenge of
cervical cancer elimination within the time frame, against the
backdrop of COVID-19.
Community Awareness and Attitudes Toward HPV
Vaccine
Public knowledge and awareness of HPV-associated diseases
and HPV vaccination are crucial for vaccine acceptance among
adolescents and their parents. This is particularly true in many
LLMICs as well as some HICs, where vaccine uptake is low even
in regions where HPV vaccine is available. For example, in the
United States, the vaccine coverage in girls for a 3, 2, and 1 dose
of HPV vaccine is 63%, 52%, and 42%, respectively (30). This low
coverage is partly because of the vaccine being given in private
health clinics as part of their national immunization program
(ie, opportunistic and the need for reimbursement costs), in-
creasing HPV-vaccine specific hesitancy with inconsistent rec-
ommendation by health-care providers, and gaps in parents’
knowledge around HPV vaccination (31-33). A systematic review
of 16 studies conducted in sub-Saharan Africa found low levels
of knowledge and awareness of HPV, HPV vaccine, and cervical
cancer, yet a high level of willingness to be vaccinated (34).
Vaccine hesitancy has been flagged as one of the top 10
threats to global health by the WHO. Similar to vaccines such as
for measles, it has had a dramatic effect on HPV vaccine uptake
and coverage in some countries (35). HPV vaccine hesitancy has
surfaced based on unfounded claims that HPV vaccines are
unsafe and promote promiscuity (36,37). Misinformation
through stories from social and traditional media and conversa-
tions about people who believed they were harmed by HPV vac-
cine has also led to parents declining timely vaccination (38).
Vaccine-hesitant parents also cite other issues such as their
child being too young, low risk of a child getting HPV infection,
and mistrust of vaccines (39-41). Many studies analyzing large
HPV vaccination datasets, as well as WHO and US Centers for
Disease Control and Prevention, have found the vaccine to be
safe (42,43). Despite this, HPV vaccine coverage in Japan has
plummeted from 70% to less than 1% since 2013 because of
unconfirmed reports of severe adverse events following HPV
vaccination (44). Recent modeling data suggest that this crisis is
estimated to result in a further 5000 cervical cancer deaths
based on the current screening coverage of 30%-40% (45). A pilot
HPV vaccine introduction program in Mongolia, where the cervi-
cal cancer burden is one of the highest in Asia (46), was also dis-
rupted because of unsubstantiated negative claims about the
vaccine, resulting in one-third of target population missing out
(47). It was only after years of strong advocacy from health pro-
fessionals and researchers, as well as quality local data on the
effectiveness of HPV vaccine, that the Mongolian government is
now considering introducing the vaccine nationally (47,48).
Education around the benefits of HPV vaccination and un-
derstanding the link between HPV infection and HPV diseases
are essential in improving vaccine acceptance. The cultural con-
text and current social norms in a given country or community
also need to be considered to allay any anxiety; for example, in
ethnic minority populations, cultural sensitivities regarding
beliefs and values of sexual activity may result in reluctance to
receive HPV vaccine (49). Language barriers can also make the
informed consent process difficult (50). These barriers are not
insurmountable, and educational interventions targeted toward
adolescents, parents, and health providers can be effective
approaches to improve knowledge and willingness to be vacci-
nated (51-54). In addition, an opt-out approach for the vaccine
program may also improve vaccine coverage. The success of
these strategies has not only been seen in HICs but also led to
increased rates of HPV vaccine uptake and broad acceptance in
LLMICs such as India, Peru, Uganda, Vietnam, and Fiji (55-57).
Global partners such as WHO and the United Nations (UN)
Population Fund, UN Women (United Nations Entity for Gender
Equality and the Empowerment of Women), and the IPVS as
well as local health practitioners who are generally well
regarded and trusted in providing health recommendations
continue to educate and advocate for HPV immunization. For
school-based delivery programs, teachers and principals as well
as the Ministry of Education will need to communicate the ben-
efits of HPV vaccination.
Education is essential but not sufficient to combat vaccine
hesitancy. Governments and health policy makers play an im-
portant role by implementing policies to improve vaccine up-
take (ie, cash transfer incentives), as well as working with
media platforms (including social media), to quell any anti-
vaccine misinformation, by providing and showing only credi-
ble, science-based information (35). Increasing transparency in
policy-making decisions related to vaccinations by focusing on
safety and trust issues is one way to improve public awareness
and confidence (58).
In the current COVID-19 pandemic, the acute uncertainty
around the virus and the massive influx of misinterpreted, ma-
nipulated, and malicious information have caused an
“infodemic” problem, with rising anxiety and conspiracy theo-
ries among the general public (59). Recent surveys of up to 2200
individuals in France and the United States suggest that 1 in 4
will not use a vaccine against SARS-CoV-2 when it becomes
available (60,61), and only 30% of people would be willing to re-
ceive the vaccine soon after it becomes available (61).
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Surprisingly, more than one-third of those who would refuse
vaccination were among low-income people (who are generally
more exposed to infectious diseases) and were young women
(aged 18-35 years, who play a crucial role regarding childhood
vaccination) (60). These individuals are also most likely to be
hesitant about routine child and adolescent vaccination, which
is a major concern for public health. Additional intervention re-
search is needed to improve vaccine acceptance for COVID-19
vaccine and also all other vaccines in the routine immunization
program.
There are more than 180 COVID-19 vaccines in development.
The success or failure of any COVID-19 vaccine is likely to be
crucial for vaccination acceptance more broadly. A safe and ef-
fective COVID-19 vaccine will improve vaccine confidence in
many people and may lead to higher overall vaccine uptake.
However, a failed vaccine, one in which there are major postli-
censure safety signals, will risk public backlash with devastat-
ing consequences for other COVID-19 vaccines as well as
routine childhood vaccines, including HPV (62). Like with HPV
vaccine, communications and trust in the government and its
health systems are going to be crucial in countering vaccine
hesitancy and any conspiracy theories. The public health com-
munity will also have an important role in assisting families
and communities to distinguish between facts and conspiracy
theories around COVID-19 and vaccination in general (59). This
includes designing information materials that specifically ad-
dress concerns around COVID-19 and educational campaigns
regarding vaccination using both traditional and social media
platforms to advise on the benefits and risks, as well as target-
ing misinformation (61).
Delivery Strategies for HPV Vaccine
The target population for HPV immunization is young adoles-
cents (younger than 15 years of age) receiving 2 or potentially
even 1 dose of HPV vaccine. High vaccine coverage is key to en-
suring the success of any HPV vaccine program. School-based
programs generally yield higher coverage than health center de-
livery in both HICs and LLMICs (63,64). The 3-dose coverage rate
in Bhutan dropped from 99% to around 68% when the country
switched from a school-based program to routine delivery
through health centers; the government subsequently reverted
back to a school-based program and achieved greater than 90%
coverage (65). Although school attendance is generally lower in
LLMICs, particularly as adolescents grow older, the final year of
primary school may be considered an ideal time for vaccination
to minimize the need to capture out-of-school children, thereby
maximizing coverage. Modeled data have found an increased
benefit of HPV vaccination among 9-year-old girls as compared
with previous estimates of cervical cancer burden, amounting
to a further 51% increase in cervical cancer deaths averted, with
the greatest benefit in the WHO African region (66). Primary
school completion rates among LLMICs are relatively high, at
around 62% for sub-Saharan Africa and 88% for South Asia, giv-
ing confidence that a primary school-based program would
reach most girls (67), although community outreach programs
are still crucial in capturing out-of-school girls. School-based
HPV vaccine programs need to be driven by government sectors
including the departments of health and education to ensure
high vaccine coverage and success of the program.
Incorporating HPV immunization with other school and ado-
lescent health programs, as well as the co-administration of
other adolescent vaccines, can also alleviate logistical
constraints (68). There is also the possibility of vaccinating
younger children (younger than 9 years old) and infants if it
works, because the coverage of childhood vaccinations (ie,
Hepatitis B, polio) is generally high, and co-administration of
vaccines can also reduce health-services burden in LLMICs (40).
This might negate some of the stigmatism and vaccine hesi-
tancy associated with HPV vaccination during adolescence (ie,
childhood vaccination to prevent adult cancer). Furthermore, in
many LLMICs, child marriage and/or child sexual abuse still oc-
cur at an alarming rate, with serious impact in life (ie, early
pregnancy, mental health, disrupted education, and limiting op-
portunities for career and vocational advancement).
Approximately 15% of girls were married by the age of 15 years
in West and Central Africa (69), and a study conducted in
Cambodia, Haiti, Kenya, Malawi, Swaziland, Tanzania, and
Zimbabwe found that more than 25% of children and adoles-
cents had experienced some form of sexual violence (70).
Therefore, offering HPV vaccination to younger children (youn-
ger than 9 years old) may actually protect a large proportion of
girls in LLMICs who are at an increased risk of cervical cancer
(71). A phase III randomized controlled trial in the Gambia is
currently ongoing to assess the immunogenicity of 9-valent
HPV (9vHPV) in girls aged 4 to 8 years (41).
During the COVID-19 pandemic, school closures have been
widespread with disruption of routine and/or catch-up immuni-
zations, including HPV, tetanus, diphtheria, and pertussis, that
are normally given at schools. School closures also have had an
indirect impact on health care, with health-care workers
unavailable to work because of the need to care for their chil-
dren (72). Catch-up immunization campaigns and community
outreach programs will therefore be needed to ensure children
and adolescents are protected from vaccine-preventable dis-
eases. A multi-age cohort HPV vaccination may be able to over-
come the delayed vaccine introduction or uptake as long as the
vaccine access and supply issues are addressed.
Uptake of HPV Vaccination After COVID-19
The COVID-19 pandemic is causing disruptions to livelihoods
and threatening years of progress in health, education, and life
opportunities for children and adolescents worldwide. This is
particularly true for immunization programs, where this pan-
demic has exposed gross inequalities in health. For HPV vacci-
nation in particular, this is likely to lead to heightened
inaccessibility to the vaccine in many LLMICs, which will have
major consequences. The indirect effect of economic down-
turns as a result of COVID-19 will expose many families to ex-
treme poverty that may lead to increased risk of early marriage
and early sexual activity in LLMICs. Further, food insecurity and
starvation might trigger migration and vulnerability of girls (eg,
pressures to sell sex in some places). These factors all heighten
risks for sexually transmitted infections and HPV before any
catch-up vaccine becomes available.
In this context of escalating sexual and reproductive health
risks for girls, the uptake of HPV vaccination in LLMICs is a
pressing agenda (Figure 1). The following recommendations ad-
dress the major barriers to HPV vaccination that have worsened
as a result of the pandemic.
Increase the funding available for HPV vaccines to address high
vaccine and programmatic costs. This requires commitments from
both governments and the donor community with the engage-
ment of multilateral organizations such as WHO and alliances
such as Gavi, Pan American Health Organization, Program for
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Appropriate Technology in Health, United Nations, UNICEF, and
the World Bank.
Adjust HPV vaccine recommendations and schedules to address
HPV vaccine supply shortages. This requires accelerated progress
to a single-dose regime while awaiting results from randomized
controlled trials (anticipated in the next few years), delay in the
second vaccine dose, a focus on female-only vaccination in
single-age cohorts in countries planning to introduce HPV vac-
cine, and fast-track of WHO prequalification process for new
HPV vaccine candidates.
Provide education and social marketing of the HPV vaccine in local
contexts to address low community awareness and unfavorable atti-
tudes toward HPV vaccine. National governments, with the sup-
port of UN agencies, and working with young people and their
families, should develop strategies to educate and address vac-
cine hesitancy and fears, as well as increase awareness about
HPV and HPV-associated diseases.
Make schools the primary delivery platform for the delivery of the
HPV vaccine. For most countries, retention rates to the end of pri-
mary school are very high so that school-based vaccination
could provide close to universal coverage. For those countries
with lower retention rates, complementary community-based
delivery will be needed.
Conclusions
Although a comprehensive approach of prevent, screen, and
treat is needed to eliminate cervical cancer within the lifetime
of today’s girls, HPV vaccination will have the greatest long-
term impact. The tools to achieve this are within the reach of
the global health community. Taking HPV vaccination to scale
presents an unparalleled opportunity for health gain while
working toward one of the Sustainable Development Goals 2030
(to reduce premature mortality from noncommunicable dis-
eases by one-third through prevention and treatment).
Furthermore, HPV vaccination prevents not only a majority of
cervical cancers but also a large proportion of other HPV-related
anogenital cancers (ie, vulva, vagina, penile, and anal) and
some oropharyngeal cancers, as well as anogenital warts. With
the pandemic, gains in HPV vaccine from the global health com-
munity and governments are pressing. A failure to act will lead
to countless avoidable cases of HPV-associated disease and
deaths as well as consuming billions of treatment dollars that
could otherwise be diverted to health problems where preven-
tion is not yet possible.
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